Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
-
Upload
mason-douberly -
Category
Documents
-
view
216 -
download
1
Transcript of Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
![Page 1: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/1.jpg)
Slide 1
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 2: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/2.jpg)
Imaging assessment in Neuro-Oncology
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 3: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/3.jpg)
Limitation: Early Pseudo-Progression <br />after radiochemotherapy<br />
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 4: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/4.jpg)
Slide 4
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 5: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/5.jpg)
Limitation- Determination of enhancing and non- enhancing tumor burden post antiangiogenic treatment
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 6: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/6.jpg)
Slide 6
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 7: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/7.jpg)
# 2007 Validation of RANO Criteria: Contribution of T2/FLAIR Assessment in Patients with Recurrent Glioblastoma Treated with Bevacizumab- Huang et al
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 8: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/8.jpg)
Assessment of RANO
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 9: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/9.jpg)
RANO-Endpoints and Trial Design
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 10: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/10.jpg)
# 2005- Final Results of APG101_CD_002: <br />APG101 + Reirradiation versus Reirradiation in the Treatment of Patients with Progressive Glioblastoma: Platten et al
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 11: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/11.jpg)
Results
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 12: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/12.jpg)
APG101_CD_002: Novel Biomarker for OS
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 13: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/13.jpg)
Slide 13
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 14: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/14.jpg)
Slide 14
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 15: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/15.jpg)
Slide 15
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 16: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/16.jpg)
Results for ICT-107 Ph II
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 17: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/17.jpg)
Authors conclusions/Comments
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 18: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/18.jpg)
Authors conclusions/Comments
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 19: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/19.jpg)
What “success” in a phase II trial warrants phase III evaluation?
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 20: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/20.jpg)
Future RANO efforts
Presented By Susan Chang at 2014 ASCO Annual Meeting
![Page 21: Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.](https://reader034.fdocuments.us/reader034/viewer/2022051614/551c1f415503469e4f8b5a55/html5/thumbnails/21.jpg)
Acknowledgements
Presented By Susan Chang at 2014 ASCO Annual Meeting